EMAIL THIS PAGE TO A FRIEND

Proceedings of the National Academy of Sciences of the United States of America

Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas.


PMID 26553993

Abstract

Given the highly heterogeneous character of brain malignancies and the associated implication for its proper diagnosis and treatment, finding biomarkers that better characterize this disease from a molecular standpoint is imperative. In this study, we evaluated CD146 as a potential molecular target for diagnosis and targeted therapy of glioblastoma multiforme (GBM), the most common and lethal brain malignancy. YY146, an anti-CD146 monoclonal antibody, was generated and radiolabeled for noninvasive positron-emission tomography (PET) imaging of orthotopic GBM models. (64)Cu-labeled YY146 preferentially accumulated in the tumors of mice bearing U87MG xenografts, which allowed the acquisition of high-contrast PET images of small tumor nodules (∼ 2 mm). Additionally, we found that tumor uptake correlated with the levels of CD146 expression in a highly specific manner. We also explored the potential therapeutic effects of YY146 on the cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) properties of U87MG cells, demonstrating that YY146 can mitigate those aggressive phenotypes. Using YY146 as the primary antibody, we performed histological studies of World Health Organization (WHO) grades I through IV primary gliomas. The positive correlation found between CD146-positive staining and high tumor grade (χ(2) = 9.028; P = 0.029) concurred with the GBM data available in The Cancer Genome Atlas (TCGA) and validated the clinical value of YY146. In addition, we demonstrate that YY146 can be used to detect CD146 in various cancer cell lines and human resected tumor tissues of multiple other tumor types (gastric, ovarian, liver, and lung), indicating a broad applicability of YY146 in solid tumors.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1306529
ANTI-CD31(C-TERMINAL) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1406108
Anti-MCAM antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA008848
Anti-MCAM antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2700812
Anti-MCAM antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701024
Anti-MCAM antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4502167
Anti-PECAM-1, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB1406243
Anti-PECAM1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1408616
Anti-PECAM1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB3700591 Anti-Rat IgG (H+L) antibody produced in donkey, affinity isolated antibody, buffered aqueous solution
SAB4700463
Monoclonal Anti-CD31 antibody produced in mouse, clone MEM-05, purified immunoglobulin, buffered aqueous solution
E9653 Monoclonal Anti-Endothelial Cells antibody produced in mouse, clone P1H12, purified immunoglobulin, buffered aqueous solution
WH0005175M1
Monoclonal Anti-PECAM1 antibody produced in mouse, clone 1D2-1A5, purified immunoglobulin, buffered aqueous solution
SAB1404193
Monoclonal Anti-PECAM1, (C-terminal) antibody produced in mouse, clone 4E3-1D9, purified immunoglobulin, buffered aqueous solution
339113
Tantalum(V) ethoxide, 99.98% trace metals basis
C10H25O5Ta
760404
Tantalum(V) ethoxide, packaged for use in deposition systems
C10H25O5Ta